Paltusotine, a Novel Oral Somatostatin Receptor Ligand in the Management of Acromegaly

David S McLaren^{1

2}, Robert D Murray^{1

2}

Affiliations

¹ Departments of Endocrinology, Leeds Centre for Diabetes & Endocrinology, Leeds Teaching Hospital NHS Trust, Leeds LS9 7TF, UK.
² Division of Cardiovascular and Diabetes Research, Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds LS2 9JT, UK.

Editorial

David S McLaren et al. J Clin Endocrinol Metab. 2023.

. 2023 Apr 13;108(5):e193-e194.

doi: 10.1210/clinem/dgac762.

David S McLaren^{1

2}, Robert D Murray^{1

2}

¹ Departments of Endocrinology, Leeds Centre for Diabetes & Endocrinology, Leeds Teaching Hospital NHS Trust, Leeds LS9 7TF, UK.
² Division of Cardiovascular and Diabetes Research, Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds LS2 9JT, UK.

No abstract available

Keywords: acromegaly; lanreotide; octreotide; paltusotine; somatostatin.

Comment on

ACROBAT Edge: Safety and Efficacy of Switching Injected SRLs to Oral Paltusotine in Patients With Acromegaly.
Gadelha MR, Gordon MB, Doknic M, Mezősi E, Tóth M, Randeva H, Marmon T, Jochelson T, Luo R, Monahan M, Madan A, Ferrara-Cook C, Struthers RS, Krasner A. Gadelha MR, et al. J Clin Endocrinol Metab. 2023 Apr 13;108(5):e148-e159. doi: 10.1210/clinem/dgac643. J Clin Endocrinol Metab. 2023. PMID: 36353760 Free PMC article. Clinical Trial.